SCHEMBL30009412

SCHEMBL30009412

N#CCCn1cc(-c2ccnc3[nH]ccc23)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 2/20 0.62
AURKA O14965 1/20 0.62
INCENP Q9NQS7 1/20 0.62
TPX2 Q9ULW0 1/20 0.62
GRM4 Q14833 1/20 0.54
JAK2 O60674 17/20 0.53
JAK1 P23458 12/20 0.53
JAK3 P52333 7/20 0.52
TYK2 P29597 3/20 0.52
STAT3 P40763 1/20 0.48
NUDT1 P36639 1/20 0.47
IKBKB O14920 1/20 0.47
CHUK O15111 1/20 0.47
DAPK3 O43293 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
CSF1R P07333 1/20 0.47
RET P07949 1/20 0.47
IGF1R P08069 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99373 1.00 AURKB (0.62) AURKBAURKAINCENPTPX2GRM4
SCHEMBL100283 0.93 AURKB (0.59) AURKBAURKAINCENPTPX2GRM4
SCHEMBL100379 0.91 AURKA (0.57) AURKBAURKAINCENPTPX2GRM4
Trifluoroacetic Acid SCHEMBL99804 0.90 AURKA (0.51) AURKBAURKAINCENPTPX2GRM4
SCHEMBL23543160 0.84 AURKB (0.66) AURKBAURKAINCENPTPX2GRM4
SCHEMBL20879725 0.84 AURKB (0.70) AURKBAURKAINCENPTPX2GRM4
SCHEMBL100071 0.82 AURKB (0.63) AURKBAURKAINCENPTPX2GRM4
SCHEMBL28338366 0.81 AURKB (0.65) AURKBAURKAINCENPTPX2GRM4
SCHEMBL101593 0.81 JAK2 (0.62) AURKBAURKAJAK2JAK1JAK3
SCHEMBL14052556 0.81 AURKB (0.65) AURKBAURKAINCENPTPX2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 AURKB 643/4885AURKA 422/4885INCENP 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.